CT引导下射频消融治疗33例肺癌的回顾性分析  

CT-guided radiofrequency ablation for lung cancer: a retrospective analysis of 35 cases

作　　者：罗君[1] 邵国良[1] 郑家平[1] 陈玉堂[1] 姚征[1] 曾晖[1] 郝伟远[1] 

机构地区：[1]浙江省肿瘤医院介入科、浙江省胸部肿瘤(肺、食管)诊治技术研究重点实验室,杭州310022

出　　处：《介入放射学杂志》2015年第6期530-533,共4页Journal of Interventional Radiology

基　　金：浙江省高层次创新人才培养工程基金(浙卫发2012-241号)

摘　　要：目的评价CT引导下射频消融(RFA)治疗肺癌的疗效及安全性。方法回顾性分析2007年5月至2013年8月接受RFA治疗的33例肺癌患者的35个病灶的治疗情况。所有行RFA的患者术后每3个月随访,以评估疗效和不良反应。随访截止日期为2013年12月或肿瘤出现进展。结果有完整随访数据的32例肺癌患者的34个病灶消融后1年局部控制率为85.3%。平均1年无进展生存率75.0%,其中15例原发性肺癌的1年无进展生存率为80.0%,17例转移性肺癌为70.6%。总体的中位无进展生存期(m PFS)为(18.0±1.3)个月。不同的年龄、性别、肿瘤大小、病理类型、临床分期等均与患者预期m PFS无显著相关(P>0.05)。RFA的主要不良反应为疼痛、胸腔积液及气胸,未出现危及生命的严重并发症。结论对早期或是晚期肺癌,RFA都是一种安全有效的微创治疗。Objective To investigate the efficacy and safety of CT-guided radiofrequency ablation（RFA） in treating lung tumors. Methods A total of 33 patients with lung cancer（35 lesions in total）, who were admitted to authors＇ hospital during the period from May 2007 to August 2013 to receive treatment,were enrolled in this study. RFA was carried out in all patients. After RFA the patients were followed up regularly（once every 3 months） to evaluate the therapeutic efficacy and the adverse reaction. The deadline for the following-up was November 2013, or to the time when tumor progression occurred. Results Of the total 34 lesions in 32 patients who had received RFA and had complete follow-up data, the one-year local control rate was 85.3%. The average one-year progression-free survival rate was 75.0%, among them 15 cases with primary lung cancer had a mean one-year progression-free survival rate of 80.0% and 17 cases with metastatic lung cancer had a mean one-year progression-free survival rate of 70.6%. The overall median progression-free survival（PFS） was（18.0±1.3） months. No obvious correlation existed between PFS and age,sex, tumor size, pathological type, clinical stage（P〈0.05）. The main adverse reactions of RFA were pain,hydrothorax and pneumothorax; no serious life-threatening complications occurred. Conclusion RFA is a safe, effective and minimally-invasive treatment for lung cancer, regardless of early stage or late stage of the tumor.

关 键 词：肺癌 射频消融 无进展生存期 

分 类 号：R734.2[医药卫生—肿瘤]